

Serial No.: 10/695,574 Replacement Sheet 12 Docket No.: 1003-DIV-01

FIG. 12

STABILIZING EFFECTS OF THE POLYMERS ON FGF1

TREATMENT 20°C 20°C 20°C 20°C 37°C 37°C VALUE **ED50** 0 DAYS 7 DAYS 15 DAYS 1 DAY 1 DAY 7 DAYS **FGF1 ALONE** 6 8 >20 14 7 >20 FGF1 + Heparin 8.0 1.2 6 16 15 1.4 FGF1 + Dextran T40 6 >20 >20 10 >20 7 FGF1 + DS commercial 6 8 >20 >20 7 >20 FGF1 + DS_{0.5} equiv 6 >20 8 >20 7 >20 FGF1 + DS_{0 125} equiv 6 10 >20 7 >20 >20 8 >20 Pcoo->20 >20 18 >20 P₁S 3 6 17 5 10 15 P2S 1 3 3 9 14 11 FGF1 + CM₁D 6 >20 9 >20 >20 FGF1 + CM₂D 6 .7 >20 7 >20 >20 FGF1 + CM₁DS2 0.5 1.1 6 17 2.1 16 FGF1 + CM₂DS2 2 8 15 5 >20 >20 FGF1 + CM2DPhS 8 15 >20 >20 8 >20 FGF1 + CM 2DPhSS1 2 6 18 >20 3 14 FGF1 + CM₂DES1 1 3 8 17 9 >20 FGF1 + CM2DPheS2 0.9 2 4 13 8 17 FGF1 + CM3DTyrS2 3 5 >20 >20 9 >20 FGF1 + CM₁DPalmS1 4 4 16 >20 14 >20

BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Inventors: Denis Barritault et al. Serial No.: 10/695,574 Replacement Sheet 13 Docket No.: 1003-DIV-01

FIG. 13
POTENTIATION EFFECTS ON FGF1 AND FGF2

Reference polymers	Conditions	concentrations (µg/ml)	ED50 FGF1 (ng/ml)	ED50 FGF2 (pg/ml)
	FGF ALONE	0	8	56
	Heparin	1	2	35
RGTA 2010	Pcoo-	100	4	56
RGTA 2011	P1S	100	2.5	38
RGTA 2012	P2S	100	4	41
RGTA 0040	DS commmercial	100	3	30
RGTA 1024	DS _{0.5} equiv	100	4	36
RGTA 1026	DS _{0.125} equiv	100	6	48
RGTA 1000	CM ₁ D	10	12	168
RGTA 1007	CM ₂ D	10	16	297
RGTA 1005	CM ₂ DS2	10	1	40
RGTA 1012	CM ₂ DS2	10	1.5	31
RGTA 1110	CM ₁ DPhS1	10	8	53
RGTA 1111	CM ₂ DES1	10	5	45
RGTA 1112	CM ₂ DPheS2	10	3	38
RGTA 1113	CM ₃ DTyrS2	10	2	30
RGTA 1114	CM ₁ DPalmS1	10	9	42

BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Inventors: Denis Barritault et al. Serial No.: 10/695,574 Replacement Sheet 16 Docket No.: 1003-DIV-01

FIG. 16

INHIBITORY EFFECTS OF THE POLYMERS ON THE ACTIVITIES OF LEUKOCYTE ELASTASE AND PLASMIN

	IC 50	mg/ml]	IC 50	mg/ml
Polymers	Elastase	plasmin	Polymers	Elastase	plasmin
Heparin	1.8	1	CM ₂ DSex	5	0.07
Pcoo-	100	53	CM ₃ D	>100	>100
P1S	2	0.98	CM ₃ DS _{0.5}	8	6
P2S	4.7	0.82	CM ₃ DS ₁	6	6
CM ₁ D	>100	>100	CM ₃ DS _{1.5}	4	6
CM ₁ DS _{0.5}	37	8	CM ₃ DS ₂	2	1.5
CM ₁ DS _{0.75}	24	2.5	CM ₂ DPhS1	12	2.4
CM ₁ DS ₁	20	1	CM ₂ DES1	18	3.8
CM ₁ DS _{1.5}	3	0.15	CM ₂ DPheS2	4	0.3
CM ₁ DS ₂	1	0.08	CM ₃ DTyrS2	1.8	0.15
CM ₁ DSex	1	0.035	CM ₁ DPalmS1	1.4	6
CM ₂ D	>100	>100	CM ₁ DOleicS1	. 2	9
CM ₂ DS _{0.5}	7	1	DS commercial	>100	>100
CM ₂ DS _{0.75}	5	0.7	DS _{0.5} equiv	>100	>100
CM ₂ DS ₁	2	0.5	DS _{0.25} equiv	>100	>100
CM ₂ DS _{1.5}	2	0.1	DS _{0.125} equiv	>100	>100
CM ₂ DS ₂	2	0.05	Dextran T40	>100	>100